Preclinical development of a humanised antibody to C5aR. [ 2006 - 2006 ]

Research Grant

Researchers: Prof Charles Mackay (Principal investigator) ,  Peter Whitfeld ,  Prof Fabienne Mackay

Brief description Complement factor C5a is one of the most potent inflammatory mediators in the body. We have developed a monoclonal antibody that blocks the C5a receptor in vitro, and completely shuts down disease in a mouse model of rheumatoid arthritis. We plan to develop this promising new antibody into a potent therapy to treat a range of chronic and acute inflammatory diseases. The antibody has been humanised and this will be tested in three models of inflammation (rheumatoid arthritis, sepsis and colitis) to determine the efficacy of the antibody, safety, the most effective dose, timing and route of administration. These studies are a necessary prelude to human clinical trials, which we hope to perform in approximately 24 months.

Funding Amount $AUD 124,875.00

Funding Scheme NHMRC Development Grants

Notes Development Grant